Protein may help detect early pancreatic cancer
the ONA take:
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer, according to a study published in Nature.
Raghu Kalluri, MD, PhD, and fellow researchers from The University of Texas MD Anderson Cancer Center examined GPC1-enriched exosomes (GPC1+ crExos) from the blood of patients with pancreatic cancer.
“GPC1+ crExos were detected in small amounts of serum from about 25 patients with pancreatic cancer with absolute specificity and sensitivity, importantly distinguishing patients with chronic pancreatitis from those with early- and late-stage pancreatic cancer,” said Dr. Kalluri.
They found that GPC1+ crExos levels were significantly lower in patients upon surgical removal of the tumor. Cancer exosomes, they concluded, can be isolated to provide cancer-specific information in addition to acting as a biomarker.
With routine screening through the use of MRIs or CT scans being “prohibitively expensive,” the study authors believe that GPC1+ crExos may be used as an effective detection tool in combination with imaging.
A protein encoded in the glypican-1 (GPC1) gene may allow for a non-invasive screening tool to detect early pancreatic cancer.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|